The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide.
This trial is currently open and accepting patients.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Enrollment: 12 patients (estimated)View More
June 11, 2021
Safety and tolerability data:
Of the six patients dosed at the first two dose levels (30×106 and 100×106 cells per infusion):
Of the five evaluable patients at the first two dose levels (30×106 and 100×106 cells per infusion):
View all clinical trial locations sorted by state.
Read the latest news and updates on this trial.
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message